Cyient DLM Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Aerospace & Defense | Market Cap: ₹5.3K Cr
The company is executing to a confident plan with ongoing improvements across areas. Company aims for a consistent 10% EBITDA margin as an initial milestone with aspirations to grow beyond that (Page 12).
From Cyient DLM Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹721
Market Cap
₹5.3K Cr
P/E Ratio
64.3
How does Cyient DLM Ltd rank in Aerospace & Defense?
Compare Cyient DLM Ltd against every Aerospace & Defense company this quarter on revenue, margins and earnings-call signals.
Cyient DLM Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹369 Cr, net profit ₹22 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company is executing to a confident plan with ongoing improvements across areas.
- →Significant opportunities are in the pipeline, including three large deals in advanced negotiation stages expected to impact revenue in the next 2 fiscal years.
- →Altek acquisition is expanding the footprint in North America, expected to drive higher growth due to demand for local manufacturing and political trends favoring "Made in U.S."
- →Aerospace and defense remain dominant sectors, but growth is also expected from industrial and medical sectors, leveraging Altek’s expertise.
- →Order book execution timeline varies between 9-12 months for new POs, with overall backlog spread over 18-24 months.
- →While short-term growth may vary due to program timing and order consumption rates, the medium to long-term outlook aims for around 30% CAGR with potential margin improvements.
- →FY '26 is expected to see revenue impact from current new orders and transfers ramping up progressively.
📈 Profitability & Margins
- →Company aims for a consistent 10% EBITDA margin as an initial milestone with aspirations to grow beyond that (Page 12).
- →Margins expected to improve in Q4 and beyond due to favorable business mix and ramp down of low-margin large deals (Page 13).
- →EBITDA margins for Altek business are similar currently but have a roadmap to achieve about 10% sustainably (Page 9).
- →Operating expenses impacted by one-off costs (M&A expenses, ECL provisions) that will not repeat, leading to better operating earnings going forward (Page 13, 18).
- →Order book discussions indicate conversion of several large deals in the next 1-2 years, which will positively impact revenues and profits (Page 8, 18).
- →Organic growth expected to ease with some softness in the first half of next financial year, with stronger growth and margin expansion later (Page 13).
- →Overall, cautious optimism on steady revenue growth and margin improvement over coming quarters.
🏗️ Capital Expenditure Plans
- →The company has excess capacity currently and does not foresee a need for substantial CAPEX expansion at the moment.
- →Incremental CAPEX additions are planned during the year and will be communicated as funds are utilized.
- →About ₹190 crores of IPO proceeds are expected to be used for working capital by the end of the year, with another ₹100 crores reserved for the next financial year's working capital requirements.
- →10% of the IPO proceeds were earmarked for inorganic growth, a portion of which has already been used for acquisitions, including the Altek acquisition.
- →Supply chain synergies are being explored to add value, including key components and distribution spend optimization.
💰 Fundraising & Capital Structure
- →The company has utilized IPO proceeds for acquisitions and repaid all external borrowings, indicating no immediate new debt.
- →Working capital and CAPEX usage so far is lower than expected, with about ₹135 crores used, expected to reach ₹190 crores by year-end and another ₹100 crores next financial year.
- →There is no mention of any current plans for new fundraising via debt or equity.
- →The company has excess capacity and therefore no immediate need for substantial CAPEX expansion that would require new funding.
- →Overall, no specific current or future fundraising through debt or equity is indicated in the document.
📋 Order Book & Pipeline
- →Consolidated order backlog stands at ₹2,142.9 crore, including ₹291.5 crore from Altek.
- →Standalone order backlog (excluding Altek) is approximately ₹1,850 crore.
- →Execution timeline for new POs varies: 9-12 months from PO to meaningful revenue; overall execution spans 18-24 months depending on client needs.
- →Altek has a shorter sales cycle with 50-60% visibility at the start.
- →Some large deals are in advanced negotiation, but specifics on deal quantum remain undisclosed; large deals expected to impact FY 2026 and beyond.
- →Order backlog has seen some decline due to consumption of existing large orders but a strong pipeline above $1 billion in B2B opportunities is being pursued.
- →No significant new client advances expected soon; free cash flow positive this quarter.
- →Challenges include timing shifts in awards and extended sales cycles typical of aerospace & defense sectors.
Key Metrics
Frequently Asked Questions
What were Cyient DLM Ltd Q3 FY25 results?
The company is executing to a confident plan with ongoing improvements across areas. Company aims for a consistent 10% EBITDA margin as an initial milestone with aspirations to grow beyond that (Page 12).
What is Cyient DLM Ltd share price analysis?
Cyient DLM Ltd currently shows a neutral. The stock trades at a P/E of 64.3 with a market cap of ₹5,278 Cr. Investors should review the full earnings analysis for detailed insights.
Is Cyient DLM Ltd planning capital expenditure?
The company has excess capacity currently and does not foresee a need for substantial CAPEX expansion at the moment.
Keep Cyient DLM Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.